Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 1

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 1
Chunk 1
---
 as a subcutaneous injection. It is approved to treat the following autoimmune diseases in the United States, Canada and Mexico (collectively, North America) and in the European Union:

Condition Principal MarketsRheumatoid arthritis (moderate to severe) North America, European UnionPsoriatic arthritis North America, European UnionAnkylosing spondylitis North America, European UnionCrohn's disease (moderate to severe) North America, European UnionPlaque psoriasis (moderate to severe chronic) North America, European UnionJuvenile idiopathic arthritis (moderate to severe polyarticular) North America, European UnionUlcerative colitis (moderate to severe) North America, European UnionNon-radiographic axial spondyloarthritis European UnionPediatric Crohn's disease (moderate to severe) North America, European UnionHidradenitis suppurativa (moderate to severe) North America, European UnionPediatric enthesitis-related arthritis European UnionNon-infectious intermediate, posterior and panuveitisNorth America, European UnionPediatric ulcerative colitis (moderate to severe)North America, European UnionPediatric uveitisNorth America, European Union

1     |  2024 Form 10-K

Humira is also approved in Japan for the treatment of intestinal Behçet's disease, generalized pustular psoriasis, and pyoderma gangrenosum.

Humira is sold in numerous other markets worldwide, including Japan, China, Brazil and Australia.

Skyrizi.    Skyrizi (risankizumab) is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. It is a biologic therapy approved to treat the following autoimmune diseases in North America, the European Union and Japan:ConditionPrincipal MarketsPlaque psoriasis (moderate to severe)North America, European Union, JapanPsoriatic arthritisNorth America, European Union, JapanCrohn's disease (moderate to severe)North America, European Union, JapanUlcerative colitis (moderate to severe)U.S., Canada, European Union, Japan

Skyrizi is also approved in Japan for the treatment of erythrodermic psoriasis in patients who have an inadequate response to conventional therapies, for generalized pustular psoriasis, and for palmoplantar pustulosis in patients who have an inadequate response to conventional